David Andrew Sandham

This inventor holds 19 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Novartis Ag, Other. Active years: 2005-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Andrew Sandham. Retrieved from https://idiyas.com/inventor/david-andrew-sandham

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 4)

% Patents Active = 52.6

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 5.4

ph-index = 4

Forward Citations = 46(Granted Patents)

Location History:

Horsham, West Sussex, GB (2008)
Horsham, GB (2005 - 2023)

Company Filing History:

17 out of 3,977

Novartis Ag

patents

2 out of 834,513

Other

patents

Years Active: 2005-2023

Loading Chart...

Areas of Expertise:

Carboxamide Derivatives

Autotaxin Inhibitors

Pyrrolopyridine Derivatives

Organic Compounds

Quinoline-2-One Derivatives

PDE5 Inhibitors

CRTH2 Antagonists

Purine Derivatives

Inflammatory Conditions

Allergic Conditions

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11672782 - Carboxamide derivatives (2023-06-13),

2. 10195181 - Carboxamide derivatives (2019-02-05),

3. 10183025 - Autotaxin inhibitors (2019-01-22),

4. 9763957 - Autotaxin inhibitors (2017-09-19),

5. 9403810 - Carboxamide derivatives (2016-08-02),

6. 9334271 - Purine derivatives and their use in the treatment of disease (2016-05-10),

7. 9169251 - Pyrrolopyridine derivatives and their use as CRTH2 antagonists (2015-10-27),

8. 8791256 - Pyrrolopyridine derivatives and their use as CRTH2 antagonists (2014-07-29),

9. 8470848 - Organic compounds (2013-06-25),

10. 8455645 - Pyrrolopyridine derivatives and their use as CRTH2 antagonists (2013-06-04),

11. 8431703 - Pyrrolopyridine compounds and their use in treating disease (2013-04-30),

12. 7888383 - Organic compounds (2011-02-15),

13. 7745462 - Quinoline-2-one derivatives for the treatment of airways diseases (2010-06-29),

14. 7678826 - Organic compounds for the treatment of inflammatory or allergic conditions (2010-03-16),

15. 7666878 - Pyrrolopyridine derivatives and their use as Crth2 antagonists (2010-02-23),

Title: David Andrew Sandham: Innovator in Pharmaceutical Chemistry

Introduction

David Andrew Sandham is a prominent inventor based in Horsham, GB, with a remarkable portfolio that includes 19 patents. His work primarily focuses on pharmaceutical chemistry, where he has made significant contributions to the development of innovative compounds that hold therapeutic potential.

Latest Patents

Among his most recent patents are advancements in carboxamide derivatives. These patents provide a compound of formula (I) or a pharmaceutically acceptable salt thereof, along with a method for manufacturing these compounds. The inventions also detail their therapeutic uses and offer a combination of pharmacologically active agents within a pharmaceutical composition. This groundbreaking work exemplifies his dedication to enhancing medical treatments through innovative chemical solutions.

Career Highlights

Throughout his career, David has contributed to leading pharmaceutical companies, notably Novartis AG. His experience in such esteemed organizations underscores his expertise in the field and the impact of his inventions on the pharmaceutical industry. His innovative mindset continues to drive advancements in drug development.

Collaborations

David has collaborated with notable professionals, including Kamlesh Jagdis Bala and Simon James Watson. These partnerships reflect his ability to work synergistically with other experts, enhancing the potential for groundbreaking innovations in pharmaceutical research.

Conclusion

David Andrew Sandham's contributions to the field of pharmaceutical chemistry through his extensive patent portfolio are commendable. His innovative developments in carboxamide derivatives pave the way for new therapeutic avenues, showcasing his importance as an inventor in the industry. As his career progresses, his impact on pharmaceutical advancements is undoubtedly set to grow.

Profile summary based on public USPTO records.